comprehensive -WSS

comprehensive

author：knowledge 2025-09-30 14:58:29 - browse：3424

LONDON — AstraZeneca said Friday an experimental drug tamped down the progression of a certain type of breast cancer in a Phase 3 trial, a win for the company after the same drug produced underwhelming results in a lung cancer trial over the summer.

The drug, called datopotamab deruxtecan or Dato-DXd for short, succeeded on one of its primary endpoints of improving progression-free survival compared to chemotherapy in certain breast cancer patients who had previously been treated with other therapies.

AstraZeneca, which is developing Dato-DXd with partner Daiichi Sankyo, said that the data for the other primary endpoint of overall survival were not “mature” as of this interim analysis, but that there was a positive trend. The trial is continuing.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Cassava reveals details — and problems — with Alzheimer's study

WSS

Eli Lilly to pay $200M for Beam’s stake in gene

FDA does about

Congress gives doctors Medicare pay bump

FogPharma raises $145 million in rare Series E round

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

Clinical trials giant ICON acquires HumanFirst

hotspot

comprehensive

Wikipedia

After affirmative action ruling, medical educators look to 'holistic review'

The pink breast cancer awareness ribbon needs a redesign

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Congress gives doctors Medicare pay bump

Dobbs anniversary: the lost opportunity of abortion as health care

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

Medical leaders decry Supreme Court decision on affirmative action

Physician subsidies by hospitals soar in wake of No Surprises Act

Dobbs anniversary: the lost opportunity of abortion as health care

RaDonda Vaught to speak at CommonSpirit event on patient safety

leisure time

FDA does about

In search for therapies for solid tumors, companies turn to claudin

First Opinion Podcast: How to protect health care in times of war

Emergency medicine has repudiated 'excited delirium.' Now what?

CDC recommends rationing of RSV shot due to shortages

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

entertainment

knowledge

explore

Wikipedia